Roche Licenses Sarepta’s DMD Therapy for US$2.88 B

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 12 (Table of Contents)

Published: 24 Dec-2019

DOI: 10.3833/pdr.v2019.i12.2481     ISSN: 1756-7874

Section: Licensing



Building its gene therapy presence, Roche has agreed to license the ex-US rights to Sarepta Therapeutics’ gene therapy SRP-9001, (AAVrh74...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details